Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 9.32
SGNT's Cash to Debt is ranked higher than
90% of the 921 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. SGNT: 9.32 )
SGNT' s 10-Year Cash to Debt Range
Min: 1.66   Max: No Debt
Current: 9.32

Equity to Asset 0.72
SGNT's Equity to Asset is ranked higher than
85% of the 842 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. SGNT: 0.72 )
SGNT' s 10-Year Equity to Asset Range
Min: -1.15   Max: 0.77
Current: 0.72

-1.15
0.77
Interest Coverage 6.64
SGNT's Interest Coverage is ranked higher than
64% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 176.76 vs. SGNT: 6.64 )
SGNT' s 10-Year Interest Coverage Range
Min: 6.64   Max: 9999.99
Current: 6.64

6.64
9999.99
F-Score: 2
Z-Score: 6.11
M-Score: 0.19
WACC vs ROIC
10.97%
48.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 6.59
SGNT's Operating margin (%) is ranked higher than
71% of the 870 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.37 vs. SGNT: 6.59 )
SGNT' s 10-Year Operating margin (%) Range
Min: -258.05   Max: 12.82
Current: 6.59

-258.05
12.82
Net-margin (%) 13.80
SGNT's Net-margin (%) is ranked higher than
87% of the 870 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.90 vs. SGNT: 13.80 )
SGNT' s 10-Year Net-margin (%) Range
Min: -253.66   Max: 13.8
Current: 13.8

-253.66
13.8
ROE (%) 15.95
SGNT's ROE (%) is ranked higher than
90% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.44 vs. SGNT: 15.95 )
SGNT' s 10-Year ROE (%) Range
Min: -26.08   Max: 16.09
Current: 15.95

-26.08
16.09
ROA (%) 12.32
SGNT's ROA (%) is ranked higher than
94% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. SGNT: 12.32 )
SGNT' s 10-Year ROA (%) Range
Min: -52.59   Max: 12.27
Current: 12.32

-52.59
12.27
ROC (Joel Greenblatt) (%) 21.20
SGNT's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.08 vs. SGNT: 21.20 )
SGNT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -442.09   Max: 49.25
Current: 21.2

-442.09
49.25
Revenue Growth (3Y)(%) 5.20
SGNT's Revenue Growth (3Y)(%) is ranked lower than
51% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.30 vs. SGNT: 5.20 )
SGNT' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 46.4
Current: 5.2

0
46.4
» SGNT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

SGNT Guru Trades in Q1 2014

Steven Cohen 142,700 sh (New)
NWQ Managers 855,750 sh (+26.60%)
Jim Simons Sold Out
Joel Greenblatt 21,573 sh (-45.19%)
» More
Q2 2014

SGNT Guru Trades in Q2 2014

Paul Tudor Jones 18,200 sh (New)
Joel Greenblatt Sold Out
NWQ Managers 802,021 sh (-6.28%)
» More
Q3 2014

SGNT Guru Trades in Q3 2014

Joel Greenblatt 6,822 sh (New)
Paul Tudor Jones 12,700 sh (-30.22%)
NWQ Managers 517,326 sh (-35.50%)
» More
Q4 2014

SGNT Guru Trades in Q4 2014

Jim Simons 17,000 sh (New)
Joel Greenblatt 19,886 sh (+191.50%)
Paul Tudor Jones 26,900 sh (+111.81%)
NWQ Managers 525,491 sh (+1.58%)
» More
» Details

Insider Trades

Latest Guru Trades with SGNT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 18.70
SGNT's P/E(ttm) is ranked higher than
69% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.40 vs. SGNT: 18.70 )
SGNT' s 10-Year P/E(ttm) Range
Min: 18.76   Max: 473.95
Current: 18.7

18.76
473.95
Forward P/E 18.73
SGNT's Forward P/E is ranked higher than
84% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 67.57 vs. SGNT: 18.73 )
N/A
PE(NRI) 23.00
SGNT's PE(NRI) is ranked higher than
73% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.00 vs. SGNT: 23.00 )
SGNT' s 10-Year PE(NRI) Range
Min: 18.74   Max: 473.95
Current: 23

18.74
473.95
P/B 3.00
SGNT's P/B is ranked higher than
69% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. SGNT: 3.00 )
SGNT' s 10-Year P/B Range
Min: 2.55   Max: 5.06
Current: 3

2.55
5.06
P/S 2.70
SGNT's P/S is ranked higher than
69% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.26 vs. SGNT: 2.70 )
SGNT' s 10-Year P/S Range
Min: 0.46   Max: 3.94
Current: 2.7

0.46
3.94
PFCF 51.70
SGNT's PFCF is ranked higher than
86% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 639.25 vs. SGNT: 51.70 )
SGNT' s 10-Year PFCF Range
Min: 13.15   Max: 69.27
Current: 51.7

13.15
69.27
POCF 38.96
SGNT's POCF is ranked higher than
82% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 37.05 vs. SGNT: 38.96 )
SGNT' s 10-Year POCF Range
Min: 11.47   Max: 52.97
Current: 38.96

11.47
52.97
EV-to-EBIT 43.78
SGNT's EV-to-EBIT is ranked higher than
75% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.20 vs. SGNT: 43.78 )
SGNT' s 10-Year EV-to-EBIT Range
Min: -38.3   Max: 331.9
Current: 43.78

-38.3
331.9
Current Ratio 2.32
SGNT's Current Ratio is ranked higher than
81% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. SGNT: 2.32 )
SGNT' s 10-Year Current Ratio Range
Min: 1.57   Max: 3.71
Current: 2.32

1.57
3.71
Quick Ratio 1.60
SGNT's Quick Ratio is ranked higher than
81% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. SGNT: 1.60 )
SGNT' s 10-Year Quick Ratio Range
Min: 0.89   Max: 2.98
Current: 1.6

0.89
2.98
Days Inventory 85.98
SGNT's Days Inventory is ranked higher than
87% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.81 vs. SGNT: 85.98 )
SGNT' s 10-Year Days Inventory Range
Min: 97.42   Max: 161.55
Current: 85.98

97.42
161.55
Days Sales Outstanding 54.03
SGNT's Days Sales Outstanding is ranked higher than
84% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 78.61 vs. SGNT: 54.03 )
SGNT' s 10-Year Days Sales Outstanding Range
Min: 6.35   Max: 93.34
Current: 54.03

6.35
93.34

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 24.40
SGNT's Price/Net Current Asset Value is ranked higher than
90% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. SGNT: 24.40 )
SGNT' s 10-Year Price/Net Current Asset Value Range
Min: 4.23   Max: 8.63
Current: 24.4

4.23
8.63
Price/Tangible Book 4.20
SGNT's Price/Tangible Book is ranked higher than
68% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.88 vs. SGNT: 4.20 )
SGNT' s 10-Year Price/Tangible Book Range
Min: 2.92   Max: 5
Current: 4.2

2.92
5
Price/Median PS Value 1.00
SGNT's Price/Median PS Value is ranked higher than
75% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. SGNT: 1.00 )
SGNT' s 10-Year Price/Median PS Value Range
Min: 0.42   Max: 1.19
Current: 1

0.42
1.19
Price/Graham Number 1.90
SGNT's Price/Graham Number is ranked higher than
76% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. SGNT: 1.90 )
SGNT' s 10-Year Price/Graham Number Range
Min: 1.98   Max: 2.1
Current: 1.9

1.98
2.1
Earnings Yield (Greenblatt) 2.60
SGNT's Earnings Yield (Greenblatt) is ranked higher than
71% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. SGNT: 2.60 )
SGNT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 6.7
Current: 2.6

0.3
6.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:S06.Germany,
Sagent Pharmaceuticals Co is a Delaware corporation that was incorporated in 2011. The Company was initially founded in 2006 as Sagent Holding Co., a Cayman Islands company, it reincorporated as Sagent Pharmaceuticals, Inc., a Delaware corporation, in connection with its initial public offering, on April 26, 2011. The Company is engaged in the developing, manufacturing, sourcing and marketing injectable pharmaceutical products, which it sells primarily in the United States of America. The Company primarily focuses on generic injectable pharmaceuticals, which provide customers a lower-cost alternative to branded products when applicable patents have expired or been declared invalid, or when the products are determined not to infringe the patents of others, it offers customers, products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials and ready-to-use pre-filled syringes and premix bags. It generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. At the year end, the Company's product portfolio has grown to a total of 53 products which can be classified into the following three product categories: anti-infective, oncology and critical care. Its anti-infective products assist in the treatment of various infections and related symptoms, its oncology products are used in the treatment of cancer and cancer-related medical problems, and its critical care products are used in a variety of critical care applications and include anesthetics, cardiac medications, steroidal products and sedatives. The Company distributes its products primarily through pharmaceutical wholesalers and, to a lesser extent, specialty distributors that focus on particular therapeutic product categories, for use by a wide variety of end-users, including U.S. hospitals, integrated delivery networks and alternative site facilities. The Company's principal competitors include Fresenius Kabi, a division of Fresenius SE, Hospira, Inc., Pfizer Inc., Sandoz International GmbH, a division of Novartis AG, Teva Pharmaceutical Industries Ltd. and West-Ward Pharmaceutical Corp. The Company is subject to extensive regulation by governmental authorities in the U.S. and in other countries.
» More Articles for SGNT

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
SAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other... Mar 26 2015
Sagent Pharma founder Jeffrey Yordon to step down as CEO Mar 26 2015
Sagent Pharmaceuticals Announces Leadership Changes Mar 26 2015
Sagent Pharmaceuticals Announces Leadership Changes Mar 26 2015
7:30 am Sagent Pharma announces Jeffrey Yordon to retire as Chairman and CEO; Re-affirms FY15... Mar 26 2015
SAGENT PHARMACEUTICALS, INC. Financials Mar 21 2015
SAGENT PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report Mar 16 2015
Sagent Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Results Feb 23 2015
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Atracurium Besylate Injection,... Feb 23 2015
SAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 19 2015
Sagent beats 4Q profit forecasts Feb 19 2015
Sagent beats 4Q profit forecasts Feb 19 2015
Q4 2014 Sagent Pharmaceuticals Inc Earnings Release - Before Market Open Feb 19 2015
Sagent Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Results Feb 19 2015
Sagent Pharmaceuticals Sets Date and Time for Release of Fourth Quarter and Full Year 2014 Financial... Feb 12 2015
Sagent Pharmaceuticals Sets Date and Time for Release of Fourth Quarter and Full Year 2014 Financial... Feb 12 2015
Sagent Pharmaceuticals is in Talks with Potential Targets Jan 14 2015
SAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 12 2015
Sagent Pharmaceuticals to Present at 33rd Annual J.P. Morgan Healthcare Conference Jan 08 2015
Sagent Pharmaceuticals to Present at 33rd Annual J.P. Morgan Healthcare Conference Jan 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK